Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world tislelizumab in advanced clear cell renal cell carcinoma
ChiCTR2100047036Phase 4Recruiting
- Sponsor
- First Affiliated Hospital of Chongqing Medical University
- Start
- Sep 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tislelizumab in renal cell carcinoma (RCC), sponsored by First Affiliated Hospital of Chongqing Medical University. Primary endpoint: Objective response rate. Started Sep 2021; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on ChiCTR2100047036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100047036.